Peled Amnon
Known title: DirectorCIK: 0002048879
Associated companies
Transaction History
| SLXN | ▲ Buy | Grant | 7,576 | $0 | 2/20/2026 | View on chart |
| SLXN | ▲ Buy | Grant | 661 | $0 | 2/9/2025 | View on chart |
| SLXN | ▲ Buy | Grant | 7,576 | $0 | 2/20/2026 | View on chart |
| SLXN | ▲ Buy | Grant | 661 | $0 | 2/9/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Silexion Reports First Patient Dosed in Phase 2/3 SIL204 Trial
Silexion Therapeutics announced that the first patient has been successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The milestone indicates progress toward evaluating the drug’s safety and efficacy in a larger patient group. The announcement may influence investor interest as the company moves closer to potential regulatory submissions. The trial’s results will be key to assessing SIL204’s future development path.
Silexion Reports First Patient Dosed in Phase 2/3 SIL204 Trial. Silexion Therapeutics announced that the first patient has been successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The milestone indicates progress toward evaluating the drug’s safety and efficacy in a larger patient group. The announcement may influence investor interest as the company moves closer to potential regulatory submissions. The trial’s results will be key to assessing SIL204’s future development path.